FDA's withdrawal of an abbreviated new drug application is usually a quiet housekeeping action — a company stops marketing a generic, FDA pulls the approval, and the application drops off the books. But the process has a built-in objection right, and a Federal Register correction published June 16, 2026 — document 2026-12044 — shows what happens when a holder exercises it. The notice corrects an error in a February 20, 2026 document that had announced the withdrawal of 11 ANDAs from multiple applicants, effective March 23, 2026.
Two of those 11 should not have been on the list. The correction identifies them precisely: ANDA 078022 for propranolol hydrochloride extended-release capsules in 60 mg, 80 mg, 120 mg, and 160 mg strengths, and ANDA 090665 for lidocaine HCl injectable, 2%, both held by Masuu Global Solutions LLC, as U.S. agent for Extrovis AG, of Boca Raton, Florida. The reason they survived is a matter of timing and procedure, and the correction states it directly.
"Because Masuu Global Solutions LLC, U.S. Agent for Extrovis AG, timely requested that approval of their ANDAs not be withdrawn, the approvals are still in effect. This notice corrects that error."— Federal Register, FDA ANDA Withdrawal Correction (2026-12044), source
How does FDA withdraw an ANDA — and how does a holder stop it?
An ANDA is the approval that lets a company market a generic version of an already-approved drug. FDA periodically moves to withdraw approvals that appear dormant or that holders no longer wish to maintain, often as part of a batch notice covering many applications at once. The process is not unilateral: before a withdrawal becomes final, the holder has a window to object — to inform FDA, in the agency's words, that they do not want the approval withdrawn. A timely objection keeps the approval alive. That is exactly what happened here. The February notice swept ANDAs 078022 and 090665 into a withdrawal list, but Masuu Global Solutions, as U.S. agent for Extrovis AG, had informed FDA that it did not want those approvals withdrawn, and it did so in time. Under the governing procedure, that objection means the approvals never lapsed, and the correction restores them on the record.
The mechanics matter for the business of generics because an active ANDA is an asset. It is the legal right to sell a specific drug at a specific strength, and it carries real value — the ability to supply the market, to be listed as an available source, and to compete on price. Letting one lapse can mean surrendering a market position that is expensive to rebuild, since re-approval would require a fresh application. The objection right is the mechanism that lets a holder protect that asset against an administrative sweep, and the propranolol and lidocaine ANDAs are a concrete example of the right being used to good effect.
Why a correction notice is worth reading closely
For the deals and approvals desk, corrections like this one are more informative than they first appear. They reveal which holders are actively defending their portfolios and which are letting approvals go. The 11-ANDA batch suggests a routine cleanup; the carve-out of two — both held through the same U.S. agent for Extrovis AG — signals a company that is paying attention to its filings and intends to keep supplying propranolol extended-release capsules and 2% lidocaine injectable. Propranolol ER is a long-established cardiovascular and migraine-prophylaxis generic, and lidocaine 2% injectable is a staple local anesthetic; both are the kind of low-glamour, steady-demand products where holding an active approval is a quiet but real competitive position.
The notice also illustrates the precision of the public record. FDA does not simply re-list the surviving ANDAs; it explains the error, attributes it to the holder's timely objection, and states that the approvals are still in effect. That transparency is what makes the Federal Register a usable primary source for tracking the generic landscape — every withdrawal, every objection, and every correction is documented and citable.
The limits of the record
The correction resolves the status of the two named ANDAs but leaves the other nine untouched, meaning those withdrawals presumably stand as stated in the February notice. It does not explain why the original document erred — whether the objection was received but not processed in time, or simply overlooked — and it does not address Extrovis AG's broader commercial plans for the two products. The action type is a notice and correction, the kind of document that quietly reshapes the approved-product universe without a press release. For anyone modeling generic competition, the practical takeaway is twofold: ANDA withdrawals are reversible by a timely holder objection, and the Federal Register is where that reversal is recorded. Two approvals that looked gone in February are, as of this correction, very much alive.
Why batch withdrawals happen — and why holders sometimes let them
The existence of an 11-application batch withdrawal is itself worth understanding. FDA periodically proposes to withdraw approvals that have gone dormant, both to keep the approved-products list accurate and because maintaining an ANDA carries ongoing obligations for the holder — annual reporting, adverse-event monitoring, and program-fee exposure under the generic-drug user-fee system. For a holder that has exited a product, letting the approval lapse is a rational way to shed those obligations and costs. That is why most ANDAs swept into a withdrawal batch are not contested: the companies have genuinely moved on. The signal in a carve-out, then, is that at least one holder has not. By objecting in time for the propranolol and lidocaine applications, Masuu Global Solutions as U.S. agent for Extrovis AG indicated those two products remain part of an active commercial strategy worth the carrying cost. For competitors and procurement teams mapping who can actually supply a given generic, that distinction — dormant versus defended — is precisely the kind of intelligence the Federal Register record makes legible. The nine uncontested withdrawals tell one story about market exits; the two preserved approvals tell another about who intends to stay.
theradeals tracks ANDA approvals, withdrawals, and the procedural decisions that determine who can supply America's generic drugs.